Sintilimab is a PD-1 inhibitor and an immune checkpoint inhibitor that blocks the interaction between PD-1 and its ligand PD-L1, to restore the body's normal antitumor immune response and achieve tumor control and elimination [10]. This evidence concerns the gene CD274 and neoplasm.